This was further supported by the finding that the combination of trastuzumab with 609A did not increase the killing of N87-PDL1 cells relative to that of trastuzumab alone in the presence of PBMCs, suggesting that blockade of PD1/PDL1 signaling did not play an important role in T cell-mediated tumor cell killing in this experimental setting. The gene discussed is CD274; the disease is neoplasm.